
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers
Recruitment Status
OpenContact the research team to learn more about this study.
Fields marked with asterisk (*) are required